Phibro Animal Health Corporation: Q2 FY2024 Form 10-Q Summary
Business context and reporting period
Phibro develops, manufactures and markets animal health, mineral nutrition and performance products for food and companion animals, as well as specialty ingredients for personal care and industrial applications. The filing covers the three and six months ended December 31, 2023, compared with the prior-year periods ended December 31, 2022. The three-month period represents the company’s fiscal second quarter.
Key financial metrics
| Metric | Three months ended Dec. 31, 2023 | Year-over-year change | Six months ended Dec. 31, 2023 | Year-over-year change |
|---|---|---|---|---|
| Net sales | $249.9 million | +2% | $481.3 million | +1% |
| Gross profit | $78.6 million | +2% | $146.3 million | Flat |
| Gross margin | 31.5% | Down 10 bps | 30.4% | Down 20 bps |
| Operating income | $15.7 million | Down 1% | $15.0 million | Down $14.6 million |
| Net income (loss) | $1.3 million | Down 82% | $(6.7) million | Down $17.8 million |
| Adjusted EBITDA | $29.5 million | Down 5% | $48.1 million | Down 9% |
| Adjusted net income | $13.5 million | Down 2% | $19.0 million | Down 14% |
| GAAP diluted EPS | $0.03 | Down $0.15 | $(0.17) | Down $0.44 |
| Adjusted diluted EPS | $0.33 | Down $0.01 | $0.47 | Down $0.08 |
Six-month operating cash flow was $47.8 million, versus cash used of $13.2 million in the prior-year period. Capital expenditures were $18.4 million, business acquisitions used $3.3 million, and net cash decreased by $8.3 million to $33.0 million. Cash and short-term investments totaled $92.5 million at December 31, 2023.
At December 31, 2023, total reported debt was approximately $474.9 million, consisting of $26.0 million of current maturities, $151.0 million drawn on the revolving facility and $297.9 million of long-term debt. The revolving facility had $156.5 million of remaining availability, subject to restrictions. The company was in compliance with its debt covenants.
Working capital was $332.4 million, compared with $350.7 million at June 30, 2023. The company reported a 3.06:1 current-assets-to-current-liabilities ratio and stated that it expects adequate liquidity for at least the next twelve months, while noting that future liquidity is not assured.
Segment performance and material changes
- Animal Health: Sales increased 6% to $173.1 million in the quarter and 5% to $333.6 million for six months. Vaccines increased 31% in the quarter and 22% year to date, while MFAs and other products increased 5% and 3%, respectively. Nutritional specialties declined 6% in the quarter.
- Mineral Nutrition: Sales were essentially flat in the quarter and declined 3% for six months. Adjusted EBITDA declined 20% in the quarter and 34% year to date, reflecting lower volume, lower average selling prices and higher raw material costs.
- Performance Products: Sales declined 19% in both the quarter and six-month period, driven by lower demand for personal care ingredients and industrial chemicals. Adjusted EBITDA declined 64% in the quarter and 52% year to date.
- Profitability: Gross profit was broadly stable because stronger Animal Health results were offset by weaker Mineral Nutrition and Performance Products performance. SG&A increased 13% for six months, including unusual costs.
- Financing and foreign exchange: Six-month interest expense increased 33% to $9.2 million because of higher variable rates and increased debt. Foreign currency losses increased to $14.2 million from $5.1 million, primarily due to currency fluctuations and the devaluation of the Argentine peso.
- Cash flow: The improvement in operating cash flow reflected working-capital timing, including cash provided by accounts receivable and accounts payable, partly offset by higher inventories.
Guidance, outlook, unusual items and risks
The filing does not provide formal quantitative earnings or revenue guidance. Management expects cash on hand, operating cash flow and available financing to support ongoing needs and expects to comply with debt covenants based on its operating plan.
- Six-month results included a $10.7 million pension settlement cost, $4.2 million of Brazil employment-tax litigation costs, $0.3 million of acquisition-related cost of goods sold and $0.2 million of stock-based compensation. The prior-year period included $6.6 million of environmental remediation costs.
- Management’s adjusted measures exclude foreign-currency losses and other unusual or non-operational items. Adjusted EBITDA and adjusted net income are non-GAAP measures and may not be comparable with similarly named measures used by other companies.
- The FDA issued a final order in November 2023 revoking the approved method for detecting carbadox residues and proposed withdrawing approvals for carbadox products. Phibro requested a hearing and filed a federal lawsuit in January 2024. Mecadox sales were approximately $18 million for the twelve months ended December 31, 2023.
- Phibro has substantial operations in Israel, including three manufacturing sites and approximately 500 employees. Israeli operations represented 19% of six-month consolidated sales and 27% of consolidated assets at December 31, 2023. The Israel-Hamas conflict could disrupt operations, personnel, supply chains and logistics.
- Environmental liabilities, including the Omega Chemical Site matter, were estimated at approximately $8.5 million. The company also faces normal-course product liability, payment, regulatory and other litigation.
- Key ongoing risks include animal disease outbreaks, regulatory restrictions on antibacterials, raw-material costs and availability, currency volatility, interest rates, customer consolidation, supply-chain disruptions, environmental obligations and leverage.
Important facts for investors to verify
- Whether the FDA carbadox proceedings or litigation ultimately affect Mecadox approval and the approximately $18 million annual sales exposure.
- Whether Animal Health growth, particularly vaccines, can offset continued weakness in Mineral Nutrition and Performance Products.
- The sustainability of operating cash flow after working-capital timing benefits and the company’s ability to fund capital expenditures, dividends and debt maturities.
- Debt levels, variable-rate exposure, covenant compliance and the April 2026 maturity of the principal 2021 credit facilities.
- The magnitude and duration of foreign-currency losses, particularly those associated with Argentina and other emerging-market currencies.
- Potential operational and financial effects of the Israel-Hamas conflict, including the concentration of assets and sales in Israel.
- The final cost and approval status of environmental settlements and other contingencies.